Scientists at a pharmaceutical company in Kalamazoo, Michigan, were developing an anti-ulcer drug. It failed as an anti-ulcer drug. It accidentally lowered blood pressure. Doctors gave it to hypertension patients. Those patients grew unexpected hair all over their bodies. Someone had the idea to put it on their skin directly. Forty years later, it's in your medicine cabinet.
Kalamazoo, Michigan — The 1950s
The Upjohn Company — a pharmaceutical manufacturer based in Kalamazoo, Michigan — was in the business of developing new drug compounds in the 1950s. One of the compounds they were researching was a molecule called N,N-diallylmelamine, intended as a treatment for peptic ulcers.
It failed as an anti-ulcer drug. Unremarkable end to an unremarkable story — except for one observed side effect. The compound appeared to lower blood pressure.
In the pharmaceutical world, a failed drug with an interesting side effect is not a dead end. Upjohn's researchers pivoted. If this compound could lower blood pressure reliably, it might be valuable as an antihypertensive. They began modifying the molecule, ultimately arriving at the compound we now know as minoxidil.
An Emergency Drug for Hypertension — 1971
By the early 1970s, minoxidil had been tested enough that the FDA granted an emergency protocol allowing physicians to use it for severe, refractory hypertension — patients whose dangerously high blood pressure wasn't responding to other treatments. The original approval was for emergency use only, with a two-week treatment limit.
Doctors kept their patients on it longer than two weeks.
When you give a drug to patients for longer than intended and pay attention, unexpected things surface. What surfaced, in roughly 60 to 80 percent of patients on oral minoxidil, was hypertrichosis — excessive hair growth. Not just on the scalp. Everywhere. Face, arms, back, legs. These were hypertension patients growing body hair at rates they'd never experienced.
Hypertrichosis as a side effect of oral minoxidil was not subtle. Patients and physicians both noticed it prominently. The question that followed was the pivot point: what if you applied the drug directly to the skin instead of taking it orally?
The Experiment Nobody Was Supposed to Do
The leap from "patients on oral minoxidil are growing body hair" to "we could apply minoxidil directly to balding scalps" required a specific kind of scientific curiosity. Two physicians — Drs. Charles Chidsey, Anthony Kahn, and Paul Grant (accounts differ on exactly who did what first) — decided to test the concept directly.
The method was remarkably low-tech: they dissolved minoxidil in a solution and applied it to their own forearms. They observed hair growth in the treated areas. Proof of concept, established on their own arms in the 1970s, using a blood pressure drug.
From this starting point, the race to formalize topical minoxidil as a hair loss treatment began — with Upjohn filing a patent and the physicians who made the discovery disputing that patent in a legal battle that would run for nearly a decade.
The Full Timeline
Anti-Ulcer Compound Fails — Blood Pressure Clue Emerges
Upjohn researchers note that N,N-diallylmelamine (DAM) lowers blood pressure as an unexpected side effect. The anti-ulcer program is abandoned; antihypertensive research begins.
Clinical Trials Begin as Antihypertensive
Minoxidil enters human clinical trials for blood pressure. The drug proves effective — particularly for cases resistant to other treatments.
Emergency FDA Protocol — Hypertension Use Begins
FDA grants emergency authorization for minoxidil use in severe hypertension. Two-week limit. Physicians use it longer.
Hypertrichosis Discovered in Patients
60–80% of patients on oral minoxidil develop significant body hair growth. The observation is documented. The pivot begins.
The Forearm Experiment
Physicians apply minoxidil solution topically to their own skin and observe localized hair growth. The concept of topical minoxidil for hair loss is demonstrated experimentally.
Upjohn Files Patent for Topical Minoxidil
Upjohn secures a patent for topical minoxidil as a hair loss treatment. The physicians who made key early observations dispute this patent — triggering legal proceedings that last nearly a decade. Both ultimately received royalties in the settlement.
Oral Minoxidil Approved as Loniten
FDA approves oral minoxidil as a prescription antihypertensive under the brand name Loniten. It remains prescription-only today for blood pressure use.
Nine Years of Clinical Trials — $100 Million+ Invested
Upjohn spends more than $100 million developing and testing topical minoxidil for hair loss through FDA approval. The process involves extensive safety and efficacy trials across thousands of patients.
Rogaine Approved — World's First Hair Loss Drug
The FDA approves topical minoxidil 2% for androgenetic alopecia under the brand name Rogaine — the first FDA-approved treatment for hair loss in history. The originally proposed name "Regaine" was rejected by the FDA (reason: implied efficacy that wasn't proven). Rogaine was approved instead.
The New York Times Rains on the Parade
The day after approval, the New York Times runs a story cautioning about Rogaine's limitations — that it worked better in younger men with less hair loss, wasn't a cure, and required ongoing use. Upjohn stock falls. The drug sells anyway.
Minoxidil Goes OTC
The FDA approves minoxidil 2% for over-the-counter sale. No prescription required. Hair loss treatment becomes accessible to anyone.
5% Minoxidil Approved for Men
The FDA approves 5% minoxidil solution for men's androgenetic alopecia — stronger than the original 2% formula, with better efficacy data for male pattern baldness.
Rogaine 5% Foam Launched
Rogaine launches the foam formulation — propylene glycol-free, easier to apply, faster-drying. Becomes the preferred format for beard use in the subsequent decade.
r/Minoxbeards Discovers Beard Growth — Before the Researchers Do
A Reddit community of men using minoxidil for beard growth forms and grows to over 100,000 members. Extensive before-and-after photo documentation accumulates years before clinical researchers publish studies on beard-specific use.
First Beard-Specific RCT Published
Ingprasert et al. publish the first randomized controlled trial specifically studying minoxidil for beard growth. The research community finally catches up to what Reddit already knew.
First Systematic Review of Beard Minoxidil
Almutairi et al. publish the first systematic review and meta-analysis of topical minoxidil for facial hair — reviewing 19 RCTs. Minoxidil is confirmed superior to placebo for beard density with minimal side effects.
The Accidental Discovery Grows Your Beard Today
From a failed ulcer drug to your morning routine. Happy Head makes it even easier with a custom prescription formula delivered to your door.
FAQ
Yes — oral minoxidil (Loniten) is still prescribed for severe, refractory hypertension that doesn't respond to other medications. It's considered a last-resort antihypertensive because of its significant side effects at the doses required for blood pressure control. The low-dose oral minoxidil now used for hair loss (0.25–5mg) is far below the doses used for hypertension (typically 10–40mg/day).
The FDA rejected "Regaine" on the grounds that it implied a level of efficacy — specifically the ability to regain lost hair — that wasn't supported by the clinical evidence. The drug worked better for maintaining existing hair and regrowing recently lost hair than for restoring long-lost coverage. "Rogaine" was the approved alternative, which managed to imply the same thing while technically not directly stating it.
The discovery that minoxidil caused hair growth was collective — multiple physicians observing hypertrichosis in their oral minoxidil patients in the early-to-mid 1970s. The specific credit for first testing it topically is attributed to various parties depending on the source, which is partly why there was a patent dispute. Drs. Kahn and Grant are commonly cited as early proponents of the topical application concept; they disputed Upjohn's patent and eventually settled for royalties.